Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05829226 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
A Phase 1 study of MDS and AML, Adult Recurrent, sponsored by PureTech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 9
- Study locations
NCT05829226 is a Phase 1 study of MDS and AML, Adult Recurrent that is actively recruiting participants, run by PureTech. The registered enrollment target is 90 participants, roughly in line with the 93-participant average among 22 other MDS trials with a reported enrollment target. The trial reports 9 study locations across 8 states.
The verdict
NCT05829226, a Phase 1 study of MDS and AML, Adult Recurrent, is actively recruiting participants, sponsored by PureTech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 9
- Study locations
Study Summary
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Decitabine
- DRUG LYT-200
Study Locations (9)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine Medical Center - Orange
Florida
- Baptist Health South Florida-Miami Cancer Institute - Miami
Kentucky
- Norton Healthcare-Norton Cancer Institute - Louisville
Massachusetts
- Mass. General Hospital-Harvard - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Rhode Island
- Rhode Island Hospital - Providence
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05829226
The ClinicalTrials.gov registry entry for NCT05829226 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 93-participant average among 22 other MDS trials with a reported enrollment target. The listed sponsor is PureTech, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with MDS appearing as the primary indexed condition, and to 4 interventions - of which Venetoclax is the first listed.
NCT05829226 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05829226 about?
NCT05829226 is a clinical study titled "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)". A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
What is the current status of trial NCT05829226?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-12-12. Estimated completion is 2026-03.
What conditions does trial NCT05829226 study?
This clinical trial studies the following conditions: MDS, AML, Adult Recurrent.
What interventions are being tested in trial NCT05829226?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Decitabine (DRUG), LYT-200 (DRUG).
Who is sponsoring clinical trial NCT05829226?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05829226 being conducted?
This trial has 9 study locations across California, Florida, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
-
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.